Dividend Assets Capital LLC cut its holdings in shares of Shire PLC (NASDAQ:SHPG) by 32.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 216,582 shares of the biopharmaceutical company’s stock after selling 104,392 shares during the quarter. Dividend Assets Capital LLC owned 0.07% of Shire PLC worth $33,167,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. BNP Paribas Arbitrage SA boosted its position in Shire PLC by 93.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 10,674 shares of the biopharmaceutical company’s stock worth $1,635,000 after acquiring an additional 5,149 shares during the period. Pitcairn Co. boosted its position in Shire PLC by 26.5% during the 3rd quarter. Pitcairn Co. now owns 1,917 shares of the biopharmaceutical company’s stock worth $293,000 after acquiring an additional 401 shares during the period. Breton Hill Capital Ltd. boosted its position in Shire PLC by 19.4% during the 3rd quarter. Breton Hill Capital Ltd. now owns 5,499 shares of the biopharmaceutical company’s stock worth $842,000 after acquiring an additional 893 shares during the period. Boston Partners boosted its position in Shire PLC by 10.8% during the 3rd quarter. Boston Partners now owns 1,455,819 shares of the biopharmaceutical company’s stock worth $222,944,000 after acquiring an additional 141,586 shares during the period. Finally, Keybank National Association OH boosted its position in Shire PLC by 20.2% during the 3rd quarter. Keybank National Association OH now owns 15,232 shares of the biopharmaceutical company’s stock worth $2,333,000 after acquiring an additional 2,556 shares during the period. Hedge funds and other institutional investors own 18.27% of the company’s stock.

A number of research firms have recently weighed in on SHPG. BidaskClub downgraded Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Barclays PLC downgraded Shire PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 11th. Evercore ISI began coverage on Shire PLC in a research note on Wednesday, August 16th. They set an “outperform” rating and a $196.00 price target for the company. Royal Bank Of Canada reaffirmed a “buy” rating and set a $213.00 price target on shares of Shire PLC in a research note on Monday, October 2nd. Finally, Piper Jaffray Companies set a $159.00 price target on Shire PLC and gave the stock a “hold” rating in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. Shire PLC presently has an average rating of “Hold” and an average target price of $211.00.

WARNING: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/13/dividend-assets-capital-llc-decreases-holdings-in-shire-plc-shpg.html.

Shire PLC (NASDAQ:SHPG) traded up $0.29 on Monday, reaching $140.36. The company’s stock had a trading volume of 701,000 shares, compared to its average volume of 1,137,305. The firm has a market cap of $41,360.00, a price-to-earnings ratio of 9.65, a P/E/G ratio of 0.78 and a beta of 1.60. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. Shire PLC has a 12-month low of $137.80 and a 12-month high of $192.15.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.64 by $0.17. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The company had revenue of $3.70 billion for the quarter. During the same period in the previous year, the business posted $3.17 EPS. Shire PLC’s revenue for the quarter was up 7.1% compared to the same quarter last year. equities research analysts expect that Shire PLC will post 15 EPS for the current year.

Shire PLC Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.